1,106
Views
17
CrossRef citations to date
0
Altmetric
Review

Chronic Enteropathy In Canines: Prevalence, Impact And Management Strategies

ORCID Icon & ORCID Icon
Pages 203-214 | Published online: 06 Dec 2019

References

  • Dandrieux JRS. Inflammatory bowel disease versus chronic enteropathy in dogs: are they one and the same? J Small Anim Pract. 2016;57(11):589–599. doi:10.1111/jsap.2016.57.issue-1127747868
  • Heilmann RM, Steiner JM. Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs. J Vet Intern Med. 2018;32(5):1495–1508. doi:10.1111/jvim.1524730222209
  • Walker D, Knuchel-Takano A, McCutchan A, et al. A comprehensive pathological survey of duodenal biopsies from dogs with diet-responsive chronic enteropathy. J Vet Intern Med. 2013;27:862–874. doi:10.1111/jvim.1209323663231
  • Allenspach K, Culverwell C, Chan D. Long-term outcome in dogs with chronic enteropathies: 203 cases. Vet Rec. 2016;178(15):368.2–368. doi:10.1136/vr.103557
  • Westermarck E, Skrzypczak T, Harmoinen J, et al. Tylosin-responsive chronic diarrhea in dogs. J Vet Intern Med. 2005;19:177–186. doi:10.1111/j.1939-1676.2005.tb02679.x15822561
  • Kilpinen S, Rantala M, Spillmann T, Björkroth J, Westermarck E. Oral tylosin administration is associated with an increase of faecal enterococci and lactic acid bacteria in dogs with tylosin-responsive diarrhoea. Vet J. 2015;205(3):369–374. doi:10.1016/j.tvjl.2015.03.02126049259
  • Kilpinen S, Spillmann T, Westermarck E. Efficacy of two low-dose oral tylosin regimens in controlling the relapse of diarrhea in dogs with tylosin-responsive diarrhea: a prospective, single-blinded, two-arm parallel, clinical field trial. Acta Vet Scand. 2014;56:43. doi:10.1186/1751-0147-56-425096196
  • Kilpinen S, Spillmann T, Syrja P, Skrzypczak T, Louhelainen M, Westermarck E. Effect of tylosin on dogs with suspected tylosin-responsive diarrhea: a placebo-controlled, randomized, double-blinded, prospective clinical trial. Acta Vet Scand. 2011;53:26. doi:10.1186/1751-0147-53-2621489311
  • Makielski K, Cullen J, O’Connor A, Jergens AE. Narrative review of therapies for chronic enteropathies in dogs and cats. J Vet Intern Med. 2019;33(1):11–22. doi:10.1111/jvim.1534530523666
  • Nguyen GC. Tip of the iceberg?: the emergence of antibiotic-resistant organisms in the IBD population. Gut Microbes. 2012;3(5):434–436. doi:10.4161/gmic.2087022713268
  • Suchodolski JS, Markel ME, Garcia-Mazcorro JF, et al. The fecal microbiome in dogs with acute diarrhea and idiopathic inflammatory bowel disease. PLoS One. 2012;7:e51907. doi:10.1371/journal.pone.005190723300577
  • Minamoto Y, Otoni CC, Steelman SM, et al. Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes. 2015;6:33–47. doi:10.1080/19490976.2014.99761225531678
  • Schmitz S, Suchodolski J. Understanding the canine intestinal microbiota and its modification by pro-, pre- and synbiotics - what is the evidence? Vet Med Sci. 2016;2:71–94. doi:10.1002/vms3.1729067182
  • Chaitman J, Jergens AE, Gaschen F, et al. Commentary on key aspects of fecal microbiota transplantation in small animal practice. Vet Med Auckl. 2016;7:71–74.30050839
  • Evans JM, Lane DR, Hendy PG. The profile of small animal practice. J Small Anim Pract. 1974;15(10):595–608. doi:10.1111/j.1748-5827.1974.tb06504.x4476891
  • Wiles BM, Llewellyn-Zaidi AM, Evans KM, O’Neill DG, Lewis TW. Large-scale survey to estimate the prevalence of disorders for 192 Kennel Club registered breeds. Canine Genet Epidemiol. 2017;4. doi:10.1186/s40575-017-0053-5
  • Inoue M, Hasegawa A, Hosoi Y, Sugiura K. Breed, gender and age pattern of diagnosis for veterinary care in insured dogs in Japan during fiscal year 2010. Prev Vet Med. 2015;119(1–2):54–60. doi:10.1016/j.prevetmed.2015.02.01025746927
  • O′Neill DG, Church DB, McGreevy PD, Thomson PC, Brodbelt DC. Prevalence of disorders recorded in dogs attending primary-care veterinary practices in England. PLoS One [Internet]. 2014 [ cited February 12, 2019];9(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942437/ Accessed September 23, 2019.
  • Kathrani A, Werling D, Allenspach K. Canine breeds at high risk of developing inflammatory bowel disease in the south-eastern UK. Vet Rec. 2011;169:635. doi:10.1136/vr.d538021896567
  • Marchesi MC, Timpano CC, Busechian S, Pieramati C, Rueca F. The role of diet in managing inflamatory bowel disease affected dogs: a retrospective cohort study on 76 cases. Vet Ital. 2017;6:297–302.
  • Adams VJ, Evans KM, Sampson J, Wood JLN. Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract. 2010;51(10):512–524. doi:10.1111/j.1748-5827.2010.00974.x21029096
  • Proschowsky HF, Rugbjerg H, Ersbøll AK. Mortality of purebred and mixed-breed dogs in Denmark. Prev Vet Med. 2003;58(1–2:63–74. doi:10.1016/S0167-5877(03)00010-212628771
  • Breitschwerdt EB, Ochoa R, Barta M, Barta O, McClure J, Waltman C. Clinical and laboratory characterization of Basenjis with immunoproliferative small intestinal disease. Am J Vet Res. 1984;45(2):267–273.6608887
  • Littman MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing enteropathy and protein-losing nephropathy in Soft Coated Wheaten Terriers: 222 cases (1983–1997). J Vet Intern Med. 2000;14:68–80.10668820
  • Bonnett BN, Egenvall A, Olson P, Hedhammar A. Mortality in insured Swedish dogs: rates and causes of death in various breeds. Vet Rec. 1997;141(2):40–44. doi:10.1136/vr.141.2.409253830
  • Egenvall A, Nødtvedt A, Penell J, Gunnarsson L, Bonnett BN. Insurance data for research in companion animals: benefits and limitations. Acta Vet Scand. 2009;51(1):42. doi:10.1186/1751-0147-51-4219874612
  • Inoue M, Hasegawa A, Hosoi Y, Sugiura K. A current life table and causes of death for insured dogs in Japan. Prev Vet Med. 2015;120(2):210–218. doi:10.1016/j.prevetmed.2015.03.01825896026
  • O’Neill DG, Church DB, McGreevy PD, Thomson PC, Brodbelt DC. Longevity and mortality of owned dogs in England. Vet J. 2013;198(3):638–643. doi:10.1016/j.tvjl.2013.09.02024206631
  • Fleming JM, Creevy KE, Promislow DEL. Mortality in North American Dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. J Vet Intern Med. 2011;25(2):187–198. doi:10.1111/j.1939-1676.2011.0695.x21352376
  • Rychlik A, Nieradka R, Kander M, Nowicki M, Wdowiak M, Kolodziejska-Sawerska A. The effectiveness of natural and synthetic immunomodulators in the treatment of inflammatory bowel disease in dogs. Acta Vet Hung. 2013;61:297–308. doi:10.1556/AVet.2013.01523921342
  • Garcia-Sancho M, Rodriguez-Franco F, Sainz A, Mancho C, Rodriguez A. Evaluation of clinical, macroscopic, and histopathologic response to treatment in nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis. J Vet Intern Med. 2007;21:11–17. doi:10.1111/j.1939-1676.2007.tb02922.x17338144
  • Heilmann RM, Otoni CC, Jergens AE, Grützner N, Suchodolski JS, Steiner JM. Systemic levels of the anti-inflammatory decoy receptor soluble RAGE (receptor for advanced glycation end products) are decreased in dogs with inflammatory bowel disease. Vet Immunol Immunopathol. 2014;161(3–4):184–192. doi:10.1016/j.vetimm.2014.08.00325183017
  • Heilmann RM, Volkmann M, Otoni CC, et al. Fecal S100A12 concentration predicts a lack of response to treatment in dogs affected with chronic enteropathy. Vet J. 2016;215:96–100. doi:10.1016/j.tvjl.2016.03.00127017054
  • Marks SL, Laflamme DP, McAloose D. Dietary trial using a commercial hypoallergenic diet containing hydrolyzed protein for dogs with inflammatory bowel disease. Vet Ther. 2002;3:109–118.19750741
  • Schmitz S, Glanemann B, Garden OA, et al. A prospective, randomized, blinded, placebo‐controlled pilot study on the effect of enterococcus faecium on clinical activity and intestinal gene expression in canine food‐responsive chronic enteropathy. J Vet Intern Med. 2015;29(2):533–543. doi:10.1111/jvim.1254225776251
  • Marchetti V, Lubas G, Lombardo A, Corazza M, Guidi G, Cardini G. Evaluation of erythrocytes, platelets, and serum iron profile in dogs with chronic enteropathy. Vet Med Int. 2010 2010;1–5. doi:10.4061/2010/716040
  • Luckschander N, Hall JA, Gaschen F, et al. Activation of nuclear factor-kappaB in dogs with chronic enteropathies. Vet Immunol Immunopathol. 2010;133:228–236. doi:10.1016/j.vetimm.2009.07.01519740552
  • Menozzi A, Dall’Aglio M, Quintavalla F, Dallavalle L, Meucci V, Bertini S. Rifaximin is an effective alternative to metronidazole for the treatment of chronic enteropathy in dogs: a randomised trial. BMC Vet Res. 2016;12. doi:10.1186/s12917-016-0813-6
  • Jergens AE, Crandell J, Morrison JA, et al. Comparison of oral prednisone and prednisone combined with metronidazole for induction therapy of canine inflammatory bowel disease: a randomized-controlled trial. J Vet Intern Med. 2010;24:269–277. doi:10.1111/j.1939-1676.2009.0447.x20051005
  • Suchodolski JS, Xenoulis PG, Paddock CG, Steiner JM, Jergens AE. Molecular analysis of the bacterial microbiota in duodenal biopsies from dogs with idiopathic inflammatory bowel disease. Vet Microbiol. 2010;19(142):394–400. doi:10.1016/j.vetmic.2009.11.002
  • Pietra M, Fracassi F, Diana A, et al. Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. Am J Vet Res. 2013;74:78–83. doi:10.2460/ajvr.74.1.7823270349
  • Heilmann RM, Jergens AE, Ackermann MR, Barr JW, Suchodolski JS, Steiner JM. Serum calprotectin concentrations in dogs with idiopathic inflammatory bowel disease. Am J Vet Res. 2012;73:1900–1907. doi:10.2460/ajvr.73.12.190023176415
  • White R, Atherly T, Guard B, et al. Randomized, controlled trial evaluating the effect of multi-strain probiotic on the mucosal microbiota in canine idiopathic inflammatory bowel disease. Gut Microbes. 2017;3(8):451–466. doi:10.1080/19490976.2017.1334754
  • Otoni CC, Heilmann RM, García‐Sancho M, et al. Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease. J Vet Intern Med. 2018;32(3):999–1008. doi:10.1111/jvim.1512329624721
  • Heilmann RM, Berghoff N, Mansell J, et al. Association of fecal calprotectin concentrations with disease severity, response to treatment, and other biomarkers in dogs with chronic inflammatory enteropathies. J Vet Intern Med. 2018;32(2):679–692. doi:10.1111/jvim.1506529460444
  • Mandigers PJ, Biourge V, van Den Ingh TS, Ankringa N, German AJ. A randomized, open-label, positively-controlled field trial of a hydrolyzed protein diet in dogs with chronic small bowel enteropathy. J Vet Intern Med. 2010;24:1350–1357. doi:10.1111/j.1939-1676.2010.0632.x21054541
  • Segarra S, Martinez-Subiela S, Cerda-Cuellar M, et al. Oral chondroitin sulfate and prebiotics for the treatment of canine Inflammatory Bowel Disease: a randomized, controlled clinical trial. BMC Vet Res. 2016;10(12):49. doi:10.1186/s12917-016-0676-x
  • Kathrani A, Steiner JM, Suchodolski J, et al. Elevated canine pancreatic lipase immunoreactivity concentration in dogs with inflammatory bowel disease is associated with a negative outcome. J Small Anim Pr. 2009;50:126–132. doi:10.1111/jsap.2009.50.issue-3
  • Nelson RW, Stookey LJ, Kazacos E. Nutritional management of idiopathic chronic colitis in the dog. J Vet Intern Med. 1988;2(3):133–137. doi:10.1111/j.1939-1676.1988.tb02809.x3225807
  • Craven M, Simpson JW, Ridyard AE, Chandler ML. Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995–2002). J Small Anim Pr. 2004;45:336–342. doi:10.1111/j.1748-5827.2004.tb00245.x
  • Allenspach K, Wieland B, Grone A, Gaschen F. Chronic enteropathies in dogs: evaluation of risk factors for negative outcome. J Vet Intern Med. 2007;21:700–708. doi:10.1111/j.1939-1676.2007.tb03011.x17708389
  • Volkmann M, Steiner JM, Fosgate GT, Zentek J, Hartmann S, Kohn B. Chronic diarrhea in dogs – retrospective study in 136 cases. J Vet Intern Med. 2017;31(4):1043–1055. doi:10.1111/jvim.2017.31.issue-428703447
  • Dandrieux JRS, Lopez LM, Prakash N, Mansfield CS. Treatment response and long term follow up in nineteen dogs diagnosed with chronic enteropathy in Australia. Aust Vet J. 2019;97(9):301–307. doi:10.1111/avj.1284631328260
  • Ciorba MA. A gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc [ [Internet] 2012 [ cited March 12, 2019];10(9):960–968. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424311/ Accessed September 23, 2019.
  • Bai A-P, Ouyang Q, Xiao X-R, Li S-F. Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. Int J Clin Pract. 2006;60(3):284–288. doi:10.1111/j.1368-5031.2006.00833.x16494642
  • Weese JS. Microbiologic evaluation of commercial probiotics. J Am Vet Med Assoc. 2002;220(6):794–797. doi:10.2460/javma.2002.220.79411918274
  • Sauter SN, Allenspach K, Gaschen F, Grone A, Ontsouka E, Blum JW. Cytokine expression in an ex vivo culture system of duodenal samples from dogs with chronic enteropathies: modulation by probiotic bacteria. Domest Anim Endocrinol. 2005;29:605–622. doi:10.1016/j.domaniend.2005.04.00615941645
  • Schmitz S, Werling D, Allenspach K. Effects of ex-vivo and in-vivo treatment with probiotics on the inflammasome in dogs with chronic enteropathy. PloS One. 2015;10(3):e0120779. doi:10.1371/journal.pone.012077925799280
  • Sauter SN, Benyacoub J, Allenspach K, et al. Effects of probiotic bacteria in dogs with food responsive diarrhoea treated with an elimination diet*. J Anim Physiol Anim Nutr. 2006;90(7–8):269–277. doi:10.1111/j.1439-0396.2005.00595.x
  • Rossi G, Pengo G, Caldin M, et al. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One. 2014;9:e94699. doi:10.1371/journal.pone.009469924722235
  • D’Angelo S, Fracassi F, Bresciani F, et al. Effect of Saccharomyces boulardii in dogs with chronic enteropathies: double-blinded, placebo-controlled study. Vet Rec. 2018;182(9):258. doi:10.1136/vr.k9329212912